X

Ovarian Cancer

Ovarian Cancer

Phase III ARIEL4 Confirms Rucaparib’s Benefit in BRCA-Mutated Relapsed Ovarian Cancer

In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP inhibitor rucaparib leads to a significant improvement in PFS compared with standard-of-care CT.

The ASCO Post
05/10/2021
Analysis of Autophagy-Related Signatures Identified Two Distinct Subtypes for Evaluating the Tumor Immune Microenvironment and Predicting Prognosis in Ovarian Cancer

This study constructs an autophagy-related prognostic indicator, and identifies two promising targets in ovarian cancer. 

Frontiers in Oncology
05/10/2021

Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve

Turan et al find the presence of germline BRCA pathogenic variants is associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and...

The ASCO Post
05/07/2021
Structured Palliative Care Referrals in Recurrent Ovarian Cancer

Researchers find that implementation of a structured palliative care process is feasible, according to a pilot study of patients with recurrent ovarian cancer.

Oncology Times - Latest Articles
05/05/2021
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer

This review illustrates recent advances in identifying ovarian cancer gene mutations, including those of TP53, BRCA1/2, PIK3CA, and KRAS genes.

Cancer Management and Research
04/08/2021
The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer

The aim of this study is to explore the prognostic and predictive role of sBRCA mutations as compared to gBRCA mutations in patients who were also tested for CNVs.

03/21/2021
Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

The aim of this review is to describe the immunobiology of ovarian cancer and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration...

Cancers
04/01/2021
Secondary Cytoreduction Followed By Chemotherapy Versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer

Study investigators assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population.

The Lancet Oncology
04/01/2021
Overall Survival With Olaparib vs Placebo Maintenance in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and BRCA1/2 Mutation

The phase III SOLO2/ENGOT-Ov21 trial has shown a large numeric but statistically nonsignificant improvement in the secondary endpoint of overall survival with olaparib tablet maintenance therapy...

The ASCO Post
04/06/2021
Frailty May Impact Surgical Outcomes in Patients With Ovarian Cancer

Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the SGO 2021 Virtual Annual Meeting on Women’s Cancer.

The ASCO Post
03/21/2021
Phase III ARIEL4 Trial Confirms Benefit of Rucaparib in BRCA-Mutated Relapsed Ovarian Cancer

In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP inhibitor rucaparib led to a significant improvement in progression-free survival compared with...

The ASCO Post
03/21/2021
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation

The aim of this final analysis is to investigate the effect of olaparib on overall survival.

The Lancet Oncology
03/18/2021
Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer.

The ASCO Post
03/22/2021
The Impact of Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

The aim of the present meta-analysis is to further update the role of PLD in the treatment of recurrent ovarian cancer.

Journal of Ovarian Research
03/09/2021
Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer

Study investigators explore the association of TILs with clinicopathological characteristics and blood indicators, and to develop nomograms to predict the density of TILs in patients with high-grad

Frontiers in Oncology
02/25/2021
Gene Expression Profile Association With Poor Prognosis in Epithelial Ovarian Cancer Patients

Study investigators perform gene expression profiling of different subtypes of ovarian cancer to evaluate its association with patient overall survival and aggressive forms of the disease.

Scientific Reports
03/08/2021
Exosome-Mediated Transfer of CD44 From High-Metastatic Ovarian Cancer Cells Promotes Migration and Invasion of Low-Metastatic Ovarian Cancer Cells

This study investigates the detailed roles and mechanisms of tumor-derived exosomes in progression and metastasis of ovarian cancer in vitro.

Journal of Ovarian Research
02/24/2021
Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma

The aim of this study is to assess the clinical and prognostic significance of expression survivin in patients with ovarian cancer.

Journal of Clinical Medicine
02/21/2021
Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer

With the highest case-fatality rate among women, the molecular pathological alterations of ovarian cancer are complex, depending on the diversity of genomic alterations.

Frontiers in Cell and Developmental Biology
04/23/2021
PAX8 and MECOM Are Interaction Partners Driving Ovarian Cancer

Comprehensive genomic screens furthermore indicate an additional oncogenic role for PAX8 in renal and ovarian cancers.

Nature Communications
04/26/2021
Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer

Study investigators examine the interaction between DNA repair proteins and immune biomarkers and their association with survival in 181 cases of epithelial ovarian carcinoma. 

Cancers
04/20/2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer

This study evaluates the addition of the humanized monoclonal PD-L1 antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer.

Journal of Clinical Oncology
04/23/2021
Cytoreduction in Advanced Ovarian Cancer

Cytoreductive surgery should be considered for advanced ovarian cancer even if patients do not respond to chemotherapy, according to researchers.

Medscape
03/30/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39